sglt2 inhibitors and glp-1 receptor agonists vs. to Treat the Heart, the Kidneys the Brain Cardiorenal Protection: Potential of SGLT2

This is particularly relevant for patients using higher doses or those who experience pronounced appetite suppression

Keras (2015)

Last updated Monday, June 29, 2026

63 Considering that T2DM and MASLD can reciprocally cause and affect each other, and given liraglutides potential therapeutic characteristics for MASLD, which may be beneficial for anti-fibrosis, more aggressive use of higher doses may bring greater clinical benefits in some groups, such as those with higher-grade fibrosis with or without T2DM

Clinically, it is mainly used to treat T2DM and causes weight reduction when used in large doses (3mg/day) (83)